Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) Research & Development (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Research & Development for 4 consecutive years, with $40.9 million as the latest value for Q4 2025.

  • For Q4 2025, Research & Development fell 33.77% year-over-year to $40.9 million; the TTM value through Dec 2025 reached $148.1 million, down 34.94%, while the annual FY2025 figure was $148.1 million, 34.94% down from the prior year.
  • Research & Development was $40.9 million for Q4 2025 at Day One Biopharmaceuticals, up from $31.4 million in the prior quarter.
  • The five-year high for Research & Development was $92.1 million in Q2 2024, with the low at $15.0 million in Q1 2022.
  • Historically, Research & Development has averaged $37.0 million across 4 years, with a median of $33.4 million in 2023.
  • The largest annual shift saw Research & Development surged 186.2% in 2024 before it tumbled 60.75% in 2025.
  • Over 4 years, Research & Development stood at $26.0 million in 2022, then skyrocketed by 43.54% to $37.3 million in 2023, then surged by 65.53% to $61.8 million in 2024, then crashed by 33.77% to $40.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $40.9 million in Q4 2025, $31.4 million in Q3 2025, and $36.1 million in Q2 2025.